David J. Graham, Judy A. Staffa, Deborah Shatin, Susan E. Andrade, Stephanie D. Schech, Lois La Grenade, Jerry H. Gurwitz, K. Arnold Chan, Michael J. Goodman, Richard Platt. Incidence of Hospitalized Rhabdomyolysis in Patients Treated With Lipid-Lowering Drugs. JAMA. 2004;292(21):2585–2590. doi:10.1001/jama.292.21.2585
Author Affiliations: Office of Drug Safety,
Center for Drug Evaluation and Research, Food and Drug Administration, Rockville,
Md (Drs Graham, Staffa, and La Grenade); Center for Health Care Policy and
Evaluation, Eden Prairie, Minn (Dr Shatin and Ms Schech); Meyers Primary Care
Institute, Fallon Foundation and the University of Massachusetts Medical School,
Worcester (Drs Andrade and Gurwitz); Channing Laboratory, Brigham and Women’s
Hospital and Harvard Medical School (Drs Chan and Platt), Department of Ambulatory
Care and Prevention, Harvard Pilgrim Health Care and Harvard Medical School
(Dr Platt), and Department of Epidemiology, Harvard School of Public Health
(Dr Chan), Boston, Mass; and HealthPartners Research Foundation, Minneapolis,
Minn (Dr Goodman).
Context Lipid-lowering agents are widely prescribed in the United States. Reliable
estimates of rhabdomyolysis risk with various lipid-lowering agents are not
Objective To estimate the incidence of rhabdomyolysis in patients treated with
different statins and fibrates, alone and in combination, in the ambulatory
Design, Setting, and Patients Drug-specific inception cohorts of statin and fibrate users were established
using claims data from 11 managed care health plans across the United States.
Patients with at least 180 days of prior health plan enrollment were entered
into the cohorts between January 1, 1998, and June 30, 2001. Person-time was
classified as monotherapy or combined statin-fibrate therapy.
Main Outcome Measure Incidence rates of rhabdomyolysis per 10 000 person-years of treatment,
number needed to treat, and relative risk of rhabdomyolysis.
Results In 252 460 patients treated with lipid-lowering agents, 24 cases
of hospitalized rhabdomyolysis occurred during treatment. Average incidence
per 10 000 person-years for monotherapy with atorvastatin, pravastatin,
or simvastatin was 0.44 (95% confidence interval [CI], 0.20-0.84); for cerivastatin,
5.34 (95% CI, 1.46-13.68); and for fibrate, 2.82 (95% CI, 0.58-8.24). By comparison,
the incidence during unexposed person-time was 0 (95% CI, 0-0.48; P = .056). The incidence increased to 5.98 (95% CI, 0.72-216.0)
for combined therapy of atorvastatin, pravastatin, or simvastatin with a fibrate,
and to 1035 (95% CI, 389-2117) for combined cerivastatin-fibrate use. Per
year of therapy, the number needed to treat to observe 1 case of rhabdomyolysis
was 22 727 for statin monotherapy, 484 for older patients with diabetes
mellitus who were treated with both a statin and fibrate, and ranged from
9.7 to 12.7 for patients who were treated with cerivastatin plus fibrate.
Conclusions Rhabdomyolysis risk was similar and low for monotherapy with atorvastatin,
pravastatin, and simvastatin; combined statin-fibrate use increased risk,
especially in older patients with diabetes mellitus. Cerivastatin combined
with fibrate conferred a risk of approximately 1 in 10 treated patients per
Conclusions Published online November 22, 2004 (doi:10.1001/jama.292.21.2585).
Disorders of muscle, ranging in severity from asymptomatic creatine
kinase elevation to rhabdomyolysis, are among the most discussed adverse effects
associated with use of lipid-lowering agents, especially 3-hydroxy-3-methylglutaryl
coenzyme A reductase inhibitors (statins).1- 5 Fibric
acid derivatives (fibrates) have also been associated with primary muscle
injury, especially when used in combination with a statin.6- 11
The epidemiology of statin-associated and fibrate-associated myopathy
is poorly described, with most attention focused on rhabdomyolysis. Based
on review of case reports, older age, female sex, low body mass index, hypothyroidism,
diabetes mellitus, and impaired renal or hepatic function have been cited
as potential risk factors for rhabdomyolysis,10,11 but
these have not been confirmed by clinical trials or observational studies.
Myopathy, defined as a serum creatine kinase level of more than 10 times the
upper limit of normal, has been estimated to occur in 0.1% to 0.5% of patients
treated with statins during randomized controlled trials.10 However,
the incidence of rhabdomyolysis has not been reliably estimated. The product
labeling for some statins presents incidence estimates for myopathy and rhabdomyolysis
combined, although in labeling for other statins the occurrence of rhabdomyolysis
is described as rare.12,13 One
epidemiologic study estimated the incidence of myopathy associated with lipid-lowering
drugs at 2.3 per 10 000 person-years of treatment and suggested that
fibrate use as monotherapy conferred a 5.5-fold increased risk compared with
statin use.14 Another study reported 1 case
of rhabdomyolysis among 2935 patients treated concurrently with a statin and
fibrate.15 Two separate analyses, based on
case reports submitted to the US Food and Drug Administration, found that
reporting of rhabdomyolysis was greater for simvastatin and cerivastatin than
for other statins,16 and that reporting of
fatal rhabdomyolysis was 17- to 79-fold greater for cerivastatin than for
Following the withdrawal of cerivastatin from the US market in August
2001 because of high reporting of rhabdomyolysis in association with its use,18 we conducted this study to estimate the incidence
of rhabdomyolysis in patients treated with statins and fibrates, alone and
in combination, in the ambulatory setting.
Inception cohorts of statin and fibrate users were established retrospectively
from patients enrolled in 11 geographically dispersed US health plans, which
included independent practice associations, staff, and group-model health
maintenance organizations.19,20 Each
of these health plans provides pharmacy benefits to its enrollees and has
automated claims files covering prescription drugs, outpatient medical encounters,
hospitalizations, and medical procedures. Using prescription claims, a separate
inception cohort was created for each statin (atorvastatin, cerivastatin,
fluvastatin, lovastatin, pravastatin, simvastatin) and fibrate (fenofibrate,
gemfibrozil) marketed in the United States from January 1, 1998, through June
30, 2001. A patient was entered into an inception cohort if on the date of
first prescription with an administered lipid-lowering drug during the study
period, there had been no prescription for the same drug in the preceding
180 days. With drug switching, a patient could contribute exposure to more
than 1 cohort.
Person-time on drug was estimated for each patient based on the days
supply field from his/her prescription claims. To account for imperfect compliance,
gaps of less than 30 days between the expected and actual fill-date of successive
prescriptions were counted as exposed days as was the 30-day period following
the end of a patient’s final prescription within a given cohort. Person-time
within each drug cohort was classified as either monotherapy or combined statin-fibrate
therapy, to permit separate risk estimates to be obtained for each type of
To identify potential cases of rhabdomyolysis, medical records were
sought and abstracted for selected hospitalizations of inception cohort members
occurring during the study period. Hospitalization claims were used to flag
the following discharge diagnoses possibly indicative of severe muscle injury:
a primary or any secondary discharge diagnosis (International
Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] code) of myoglobinuria (791.3); a primary discharge
diagnosis of other disorders of muscle, ligament, and fascia (728.89, includes
rhabdomyolysis), myositis (729.1), myopathy (359.4, 359.8, 359.9), polymyositis
(710.4), muscle weakness (728.9), musculoskeletal symptoms of the limbs (729.8X),
or adverse effect from antihyperlipidemic agents (E942.2); any secondary discharge
diagnosis for a muscle-related disorder (any of the previous diagnoses) plus
a laboratory claim for serum creatine kinase measurement within 7 days before
admission or after discharge; a primary discharge diagnosis of acute renal
failure (584 and subcodes) plus any muscle-related secondary diagnosis; or
any discharge diagnosis of acute renal failure plus a serum creatine kinase
test within 7 days before admission or after discharge.
Information abstracted from each medical record included age, sex, symptom
onset, hospital course, outcome, laboratory test results (urine myoglobin,
and serum creatine kinase, potassium, alanine aminotransferase, aspartate
aminotransferase, creatinine), and drug exposure history (if any). Past history
of diabetes mellitus, liver disease, and renal failure was identified from
automated claims data.
Medical record abstracts were reviewed by 3 authors (D.J.G., J.A.S.,
and L.L.G.) who were blinded to statin or fibrate exposure status. A patient
was classified as having rhabdomyolysis if medical record review showed that
severe muscle injury was present at the time of hospital admission and, in
addition, the patient’s physician had made a diagnosis of rhabdomyolysis
or the patient’s creatine kinase level was more than 10 times the upper
limit of normal. Severe rhabdomyolysis was defined as the subset of these
patients with serum creatine kinase exceeding 10 000 IU/L or with serum
creatine kinase of more than 50 times the upper limit of normal.
Relative risk (RR) estimates of rhabdomyolysis adjusted for age, sex,
and diabetes mellitus were calculated using Poisson regression. Incidence
rates of rhabdomyolysis per 10 000 person-years of treatment with 95%
confidence intervals (CIs) and number needed to treat to observe a case of
rhabdomyolysis were calculated.21 All analyses
were performed using Stata version 7 (StataCorp, College Station, Tex). This
study was approved by institutional review boards for the participating health
A total of 252 460 patients contributed 225 640 person-years
of monotherapy for a statin or fibrate and 7300 person-years of combined therapy
(Table 1). The proportion of patients
with diabetes mellitus was greater among fibrate users, consistent with the
use of these agents to treat hypertriglyceridemia.22 Because
usage of fluvastatin and lovastatin was very low, these drugs were excluded
from subsequent analyses.
Each of the statins included in this study were in use at the start
of the study, with cerivastatin appearing during the first quarter of 1998
(Figure). Cerivastatin use increased
slowly but did not achieve high-volume use within the health plans studied.
Atorvastatin use increased steadily with a corresponding decline in pravastatin
use through 2003.
Of 194 potential cases, hospital medical records were obtained for 174
patients (90%). In 139 records, the serum creatine kinase level was less than
10 times the upper limit of normal and there was no diagnosis of rhabdomyolysis
in the chart. Acute myocardial infarction was responsible for creatine kinase
elevations in 3 patients and 1 patient, admitted for elective surgery, developed
rhabdomyolysis postoperatively. The remaining 31 patients met the case definition
for incident rhabdomyolysis. Seven of these patients were excluded from analysis
because their rhabdomyolysis event occurred during a period when, according
to automated claims data, they were not exposed to a lipid-lowering drug and
therefore were not contributing exposed time to an inception cohort. In each
of these instances, however, the hospital record explicitly noted that the
patient had been taking a statin at the time of the event (atorvastatin-1,
cerivastatin-1, fluvastatin-1, pravastatin-3, simvastatin-1). Among these
patients, 2 died, of whom 1 patient also underwent hemodialysis.
Within the inception cohorts, there were 16 cases of rhabdomyolysis
with monotherapy (13 with a statin and 3 with gemfibrozil) and 8 cases with
combined statin-fibrate therapy. The mean (SD) age of patients with rhabdomyolysis
was 64.6 (2.7) years (Table 2). Twenty-three
patients (94.4%) had symptoms of muscle pain or weakness preceding hospitalization,
with a mean symptom duration of 6.9 days (range, 1-30 days) before admission.
Eighteen patients (75%) had severe rhabdomyolysis. With monotherapy, cases
occurred after a mean length of therapy of 348 days for atorvastatin or simvastatin
(range, 21-1050 days), 56 days for cerivastatin (range, 21-106 days), and
77 days for gemfibrozil (range, 21-179 days). The mean time to onset after
initiation of combined statin-fibrate therapy was 32 days (range, 18-78 days).
Mean hospital length of stay was 5.7 days (range, 1-11 days), during which
all patients were treated with hydration and 10 patients (41.6%) with diuretics.
Two patients (8.3%) required hemodialysis, 1 of whom died. Five patients were
taking thyroid hormone therapy and 1 had concurrent exposure to erythromycin.
No patients were taking an azole antifungal agent or cyclosporine.
The incidence rates of rhabdomyolysis with monotherapy of atorvastatin,
pravastatin, and simvastatin were statistically indistinguishable, with a
summary point estimate of 0.44 per 10 000 person-years of use (95% CI,
0.20-0.84) (Table 3). A sensitivity
analysis including the 7 cases that occurred during time outside the inception
cohorts yielded a summary estimate of 0.68 (95% CI, 0.38-1.15) and the individual
incidence rates remained indistinguishable. The incidence rates for cerivastatin
and gemfibrozil as monotherapy were similar and both were more than those
for the 3 other statins analyzed (P = .002
for cerivastatin and P = .02 for gemfibrozil).
Although there were no cases with fenofibrate monotherapy, the 95% CI for
its incidence rate completely bounded that for gemfibrozil monotherapy, which
suggested comparability. The summary incidence rate per 10 000 person-years
for the 2 fibrates (fenofibrate and gemfibrozil) combined was 2.82 (95% CI,
0.58-8.24). In comparison, there were no unexposed cases during 76 681
person-years of unexposed person-time within the inception cohorts, resulting
in an incidence of 0 (95% CI, 0-0.48; P = .056).
The number needed to treat for 1 year with monotherapy to observe 1 case of
hospitalized rhabdomyolysis was 22 727 patients receiving atorvastatin,
pravastatin, or simvastatin; 1873 patients receiving cerivastatin; and 3546
patients receiving a fibrate.
The incidence rates for rhabdomyolysis for monotherapy with atorvastatin,
pravastatin, or simvastatin remained statistically indistinguishable over
time. For therapy intervals of less than 6 months, 6 to 12 months, 13 to 24
months, and more than 24 months, the incidence of rhabdomyolysis per 10 000
person-years was 0.7 (95% CI, 0.3-1.6), 0.2 (95% CI, 0.01-1.2), 0.2 (95% CI,
0.01-1.1), and 0.6 (95% CI, 0.1-2.1), respectively. A similar pattern was
observed with cerivastatin and fibrate monotherapy.
Incidence rates of rhabdomyolysis with combined statin-fibrate therapy
were higher than those observed with monotherapy (Table 3). Based on the statin-fibrate combinations for which there
were cases, the magnitude of the effect appeared to be similar regardless
of the statin and fibrate involved, with the exception of cerivastatin. For
the other statins, the composite incidence with combined use was 5.98 (95%
CI, 0.72-216) per 10 000 patient-years, although inspection of individual
cohorts suggested that the point-estimate was probably between 16.9 and 22.5
per 10 000 person-years. For combined cerivastatin-fibrate therapy, 2
separate estimates of the incidence rate of rhabdomyolysis, 1 obtained from
the cerivastatin inception cohort and 1 from the gemfibrozil inception cohort,
were similar, with point estimates ranging from 789 to 1035 per 10 000
person-years. The number needed to treat for 1 year with combined therapy
involving atorvastatin, pravastatin, or simvastatin and fibrate was 1672 patients.
With combined cerivastatin and gemfibrozil, the number needed to treat ranged
from 9.7 to 12.7 patients.
All patients with rhabdomyolysis were taking statins at daily dosages
within the dose-range recommended in product labeling (Table 4). For atorvastatin and simvastatin, 3 (27%) of 11 cases
occurred at the 40-mg dose, half the recommended maximum dose. The remaining
8 cases (73%) occurred at even lower daily doses. For cerivastatin, 3 (30%)
of 10 cases occurred at the maximum recommended dose of 0.8 mg, with the remaining
7 cases (70%) occurring at lower daily doses.
Hospitalized rhabdomyolysis with statin monotherapy was increased for
patients aged 65 years or older (RR, 5.4; 95% CI, 1.3-21.6) and the point
estimate of the RR was increased for patients with diabetes mellitus (2.9;
95% CI, 0.7-11.8). There was no increase in RR among women (0.9; 95% CI, 0.2-3.2).
The RRs of rhabdomyolysis with fibrate or cerivastatin use, as monotherapy
or combination therapy, were estimated using statin monotherapy (atorvastatin,
pravastatin, and simvastatin) as the reference. With monotherapy, fibrate
use was associated with a 5.5-fold increase (95% CI, 1.5-20.4) and cerivastatin
with a 10.0-fold increase (95% CI, 3.1-32.7) in risk compared with statin
use. Combined statin-fibrate use conferred a 12-fold increase in risk vs statin
monotherapy (RR, 12.20; 95% CI, 2.59-57.44). The risk of hospitalized rhabdomyolysis
for a patient aged 65 years or older with diabetes mellitus, treated with
both a statin and fibrate was increased 48-fold (95% CI, 5.2-446.0), translating
to a number needed to treat of 484 patients. The risk from combined cerivastatin-fibrate
use was increased 1411-fold (95% CI, 496-4013).
Using population-based inception cohorts of patients treated with various
statins and fibrates, the incidence rate of rhabdomyolysis was found to be
similar for monotherapy with atorvastatin, pravastatin, and simvastatin, currently
the 3 most widely prescribed statins in the United States.17 Compared
with statin monotherapy, fibrate use was associated with a 5.5-fold increase
in risk and the combined use of a statin and fibrate increased risk by an
additional 2-fold vs fibrate alone. The risk of rhabdomyolysis with cerivastatin
monotherapy was 10-fold greater than with other statins, and in combination
with a fibrate, was increased more than 1400-fold. With an estimated incidence
of approximately 1000 per 10 000 person-years of use, rhabdomyolysis
might have occurred in approximately 1 of every 10 patients treated with cerivastatin
and fibrate for a year. The risk of rhabdomyolysis did not appear to diminish
with longer-term use of statins or fibrates as monotherapy. Also, the occurrence
of rhabdomyolysis in the absence of statin or fibrate therapy appears to be
In the only published population-based study to our knowledge of myopathy
risk with lipid-lowering drugs, monotherapy with fibrates was associated with
a 5.5-fold increased risk vs statin monotherapy, and fenofibrate carried the
highest individual RR.14 Our study was considerably
larger, involving more than 10 times as many exposed patients, and focused
on severe disease requiring hospitalization rather than including nonhospitalized
events. In addition, the previous study included patients if their creatine
kinase level was even minimally elevated above the upper limit of normal;
whereas, in our study, creatine kinase levels for patients ranged from 15
to 1780 times the upper limit of normal.
Statin-associated rhabdomyolysis risk has been described as dose-dependent
and concentration-dependent,4,5 and
much work has been performed to identify pharmacokinetic differences between
statins in an effort to understand the mechanisms of their myotoxicity. All
statins except pravastatin are metabolized within the liver by the cytochrome
P450 system, with atorvastatin, cerivastatin, lovastatin, and simvastatin
handled by the cytochrome P450 isoenzyme 3A4 (CYP 3A4).1,23 Competitive
inhibition of CYP 3A4 by drugs, such as ketoconazole, erythromycin, or cyclosporine,
has been shown to block oxidation of these statins and increase their serum
concentration, which in turn has been cited as an explanation for increased
rhabdomyolysis risk.5,23,24 Only
1 case-patient of 24 in our study was concurrently treated with 1 of these
potent CYP 3A4 inhibitors. Pharmacokinetic complexity is further increased
with the concurrent use of fibrates and statins.25- 30
The above factors alone may not explain the RRs observed in our study.
The magnitude of increase in statin serum concentration observed with combination
use of gemfibrozil and a variety of statins only ranged from 2- to 5.5-fold.25- 30 In
contrast, we found that the risk of rhabdomyolysis with combined statin-fibrate
use was increased 12-fold vs with statin use alone. With cerivastatin, combination
use conferred more than a 1400-fold increase in risk. The occurrence of rhabdomyolysis,
as a pharmacodynamic response to combined use, appears to be disproportionate
to any expected effect on statin serum concentration. This suggests that the
mechanism underlying the occurrence of rhabdomyolysis could be nonlinear and
possibly independent of pharmacokinetic interactions.
To our knowledge, this is the first comprehensive study of rhabdomyolysis
incidence associated with statin and fibrate therapy. The use of inception
cohorts permitted the identification and classification of incident person-time,
both as monotherapy and combination therapy, and accounted for drug switching,
which is common among statin users. We used a strict case definition that
was validated by medical record review. In addition, the strategy for identifying
cases was broad and inclusive, reducing the likelihood that cases were missed.
These factors should contribute to reliable estimates of incidence rates and
RRs for rhabdomyolysis.
There were also limitations in our study. The primary analysis was based
on 24 case-patients, which could be viewed as too small for reliability. Although
this may be a relatively low number of case-patients, it represents a large
number for rhabdomyolysis. To compensate for the relative rarity of the outcome,
we assembled large exposure cohorts and applied a rigorous case-finding strategy.
For several drugs, the incidence rate estimates had wide 95% CIs, reflecting
the small number of events. Nonetheless, there was sufficient precision in
the estimates to establish the similarity in rhabdomyolysis risk for atorvastatin,
pravastatin, and simvastatin. Additionally, there was adequate statistical
power to demonstrate the impact of combined statin-fibrate use, especially
in higher risk patients such as those aged 65 years or older with diabetes
mellitus. Seven cases of rhabdomyolysis were identified during what were thought
to be periods of nonexposure to statins. Medical records indicated that all
patients were taking a statin at the time of symptom onset, demonstrating
that computerized prescription claims did not identify all statin use within
the study population. Because of the high expense of prescription statin drugs,
a common assumption made by researchers using health claims data has been
that patients would not purchase prescription medications out-of-pocket if
they could be paid for by insurance.19,20 Possible
explanations for this potential exposure misclassification include use of
free product samples, dual–health insurance coverage by case-patients
and their spouses, or use of products prescribed for others. A sensitivity
analysis showed that inclusion of these cases in the primary analysis did
not significantly alter the estimates of rhabdomyolysis risk and would not
have altered the qualitative conclusions of our study.
We also encountered one instance in which the exposure status of a case-patient
based on prescription claims was classified as fibrate monotherapy, but based
on the hospital medical record, may have involved combination therapy with
cerivastatin. Per study protocol, this patient was classified as fibrate monotherapy
for analysis purposes because exposure classification of all study patients
was based on the computerized prescription claims. Also, there was no way
to identify similar episodes of unrecognized statin use among the several
hundred thousand non–case patients for whom medical records were not
reviewed. Additional research is needed to better define the nature and magnitude
of rhabdomyolysis risk with fibrate monotherapy and to determine if risks
with gemfibrozil and fenofibrate are similar or different.
With the potential for a substantial increase in the number of patients
treated with statins over the next several years,31 our
study provides reassurance that the risk of rhabdomyolysis is relatively low
with 3 frequently prescribed statins. For patients treated with both statins
and fibrates combined, such as persons with diabetes mellitus with elevated
cholesterol and triglyceride levels, the higher risk conferred by combination
therapy may warrant that physicians instruct their patients to stop therapy
and be evaluated if symptoms suggestive of rhabdomyolysis develop.
Corresponding Author: David J. Graham, MD,
MPH, Office of Drug Safety, Center for Drug Evaluation and Research, Food
and Drug Administration, 5600 Fishers Ln, HFD-400, Rockville, MD 20857 (firstname.lastname@example.org).
Financial Disclosure: Dr Andrade
has performed consulting services and received grant support in the past from
Merck, Pfizer, and Bristol-Myers Squibb, manufacturers of lipid-lowering drugs.
Author Contributions: Dr Graham had full access
to all of the data in the study and takes responsibility for the integrity
of the data and the accuracy of the data analysis.
Study concept and design: Graham, Staffa, Shatin,
Andrade, La Grenade, Platt.
Acquisition of data: Staffa, Shatin, Andrade,
Schech, Gurwitz, Chan, Goodman.
Analysis and interpretation of data: Graham,
Staffa, Shatin, Andrade, Schech, La Grenade.
Drafting of the manuscript: Graham.
Critical revision of the manuscript for important
intellectual content: Graham, Staffa, Shatin, Andrade, Schech, La Grenade,
Gurwitz, Chan, Goodman, Platt.
Statistical analysis: Graham, La Grenade, Chan.
Obtained funding: Staffa, Gurwitz.
Administrative, technical, or material support:
Graham, Staffa, Shatin, Andrade, Schech, La Grenade, Gurwitz, Chan, Platt.
Study supervision: Staffa, Shatin, Andrade,
Funding/Support: This study was supported by
2 cooperative agreements, FD-U-002067 (UnitedHealth Group) and FD-U-002068
(HMO consortium of Harvard-Pilgrim Healthplan, Fallon Community Health Plan,
and Health Partners), from the US Food and Drug Administration.
Role of the Sponsor: The Food and Drug Administration
(FDA) did not participate in the design and conduct of the study, in the collection,
analysis, and interpretation of the data, or in the preparation, review, or
approval of the manuscript. Dr Graham and several coauthors are employees
of the FDA but functioned as investigators without direction or interference
by the FDA.
Acknowledgment: We thank Margaret J. Burgess
for her programming assistance and technical support.